Last reviewed · How we verify
VEGZELMA (BEVACIZUMAB-ADCD)
VEGZELMA (generic name: BEVACIZUMAB-ADCD) is a Vascular Endothelial Growth Factor Inhibitor [EPC] drug developed by CELLTRION. It is currently FDA-approved.
At a glance
| Generic name | BEVACIZUMAB-ADCD |
|---|---|
| Sponsor | CELLTRION |
| Drug class | Vascular Endothelial Growth Factor Inhibitor [EPC] |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Epistaxis
- Headache
- Hypertension
- Rhinitis
- Proteinuria
- Taste alteration
- Dry skin
- Hemorrhage
- Lacrimation disorder
- Back pain
- Exfoliative dermatitis
- Fatigue
Serious adverse events
- Hemorrhage
- Thromboembolic events
- Disease progression
- Hypertension
- Dehydration
- Sensory neuropathy
- Fatigue
- Diarrhea
- Vomiting
- Nausea
Key clinical trials
- Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865) for Women With Hormone Receptor-Positiv (Phase 3)
- A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in C (Phase 2)
- Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients (Phase 3)
- A Phase 1a/1b Study of 27T51, an Anti-MUC16 CAR T Cell Drug Product Administered Alone or in Combination for Participants With Recurrent or Refractory Epithelial Ovarian, Primary Peritoneal, or Fallop (Phase 1)
- A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage I (Phase 2)
- A Phase II Open Label, Randomized Study Testing the Efficacy of Retifanlimab in Combination with Bevacizumab and Hypofractionated Radiotherapy in Patients with Recurrent GBM (Phase 2)
- A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma (Phase 2)
- A Prospective Cohort Study of Integrating Radiotherapy Into Chemotherapy With Pembrolizumab and Bevacizumab in Newly Diagnosed Stage IVB Cervical Cancer (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VEGZELMA CI brief — competitive landscape report
- VEGZELMA updates RSS · CI watch RSS
- CELLTRION portfolio CI
Frequently asked questions about VEGZELMA
What is VEGZELMA?
VEGZELMA (BEVACIZUMAB-ADCD) is a Vascular Endothelial Growth Factor Inhibitor [EPC] drug developed by CELLTRION.
Who makes VEGZELMA?
VEGZELMA is developed and marketed by CELLTRION (see full CELLTRION pipeline at /company/celltrion).
What is the generic name of VEGZELMA?
BEVACIZUMAB-ADCD is the generic (nonproprietary) name of VEGZELMA.
What drug class is VEGZELMA in?
VEGZELMA belongs to the Vascular Endothelial Growth Factor Inhibitor [EPC] class. See all Vascular Endothelial Growth Factor Inhibitor [EPC] drugs at /class/vascular-endothelial-growth-factor-inhibitor-epc.
What development phase is VEGZELMA in?
VEGZELMA is FDA-approved (marketed).
What are the side effects of VEGZELMA?
Common side effects of VEGZELMA include Epistaxis, Headache, Hypertension, Rhinitis, Proteinuria, Taste alteration. Serious adverse events: Hemorrhage, Thromboembolic events, Disease progression, Hypertension.
Related
- Drug class: All Vascular Endothelial Growth Factor Inhibitor [EPC] drugs
- Manufacturer: CELLTRION — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing